Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × treosulfan × Plasma cell × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 14 Myeloid 10 Lymphoid 3 Classical hematology 2 Thoracic 1 Plasma cell 1 Genitourinary 1 Dermatologic 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 372 Lenalidomide 205 Bortezomib 200 Cyclophosphamide 178 Melphalan 134 Calcium Dobesilate 119 daratumumab 106 pomalidomide 74 carfilzomib 73 fludarabine phosphate 71 Peripheral Blood Stem Cell Transplantation 66 Thalidomide 57 Filgrastim 57 Mycophenolic Acid 56 Busulfan 55 Tacrolimus 48 Granulocyte Colony-Stimulating Factor 47 ixazomib 45 fludarabine 45 Whole-Body Irradiation 44 dexamethasone acetate 35 Cyclosporine 35 isatuximab 34 Etoposide 34 Antilymphocyte Serum 32 dexamethasone 21-phosphate 29 elotuzumab 28 Prednisone 27 auricularum 26 plerixafor 25

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05636787 2024-07-08

TreoMel

Insel Gruppe AG, University Hospital Bern

Phase 2 Recruiting

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡